PHAXIAM Therapeutics S.A.
PHXM
Classificação em ações
#39374
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Preço da ação
$0.11725176
Última sincronização: 2025-07-14
Valor de mercado
$481.50K
Variação (1 dia)
-0.20%
Variação (1 ano)
3.89%
País
FR
Negociar PHAXIAM Therapeutics S.A. (PHXM)
Categoria
Healthcare
Histórico de preços das ações de PHAXIAM Therapeutics S.A. (PHXM)
Preço de fecho mais alto: $0.11 em 2025-09-01
Preço de fecho mais baixo: $244.88 em 2014-09-01
Preço de fecho mais baixo: $244.88 em 2014-09-01
Histórico de preços das ações da PHAXIAM Therapeutics S.A. de 2014 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2025 | -93.86% |
| 2024 | -59.46% |
| 2023 | -33.86% |
| 2022 | -70.66% |
| 2021 | -72.34% |
| 2020 | 46.24% |
| 2019 | -20.11% |
| 2018 | -66.93% |
| 2017 | 58.80% |
| 2016 | -58.92% |
| 2015 | 3.13% |
| 2014 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $535.90 | 25.67% |
US
|
|
| $223.41 | 732.07% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $874.96 | 7.47% |
NL
|
